If you’ve ever struggled to catch your breath — and I mean really struggled, the kind where even walking across the room feels like a marathon — you know how lung disease doesn’t just affect your lungs. It takes over your whole life.
That’s the reality for millions of people living with COPD, pulmonary fibrosis, and the lingering lung damage that sticks around long after a COVID-19 infection has cleared. Medications help manage symptoms. Oxygen tanks become constant companions. But for a lot of patients, the question lingers: isn’t there something more?
Here at Cell La Vie in Bangkok, we’ve been asking that same question. And for the past several years, the answer has increasingly pointed toward one thing: mesenchymal stem cells, or MSCs.
Now, before your eyes glaze over — I promise this won’t be a dense scientific lecture. Think of this as a conversation. Maybe over coffee. About what’s actually happening inside damaged lungs, and how stem cell therapy is quietly changing the game for respiratory patients who’ve run out of options.
What Happens When Lungs Get Damaged
Your lungs are remarkably resilient organs. Every day they filter something like 11,000 liters of air, pulling oxygen into your bloodstream and pushing carbon dioxide out. The tissue inside them — the alveoli, those tiny air sacs where gas exchange happens — is delicate but tough.
Thing is, when that tissue gets hit hard enough, the body’s repair mechanisms start to fall behind. In COPD, cigarette smoke or environmental pollutants trigger chronic inflammation that slowly destroys the alveolar walls. Emphysema, a form of COPD, literally eats holes in your lung tissue. In pulmonary fibrosis, the opposite happens: scar tissue builds up, thickening the walls between air sacs until oxygen simply can’t cross over anymore.
Post-COVID lung damage is its own beast. Some patients who recovered from severe COVID-19 pneumonia are left with fibrosis-like scarring, persistent inflammation, and reduced lung capacity that doesn’t bounce back on its own, even months or a year after clearing the virus.
In all three scenarios, there’s a common thread: the body’s natural repair crew can’t keep up. The inflammation switch gets stuck in the “on” position. And over time, healthy functional tissue gets replaced by scars or simply destroyed.
Enter Mesenchymal Stem Cells
So what makes MSCs different from, say, taking another inhaler or bumping up your steroid dose?
The short answer is that MSCs don’t just treat symptoms — they work at the repair level. These are adult stem cells, typically sourced from umbilical cord tissue (which is what we use at Cell La Vie), and they come with a few key abilities that make them particularly interesting for lung disease.
First, they’re powerfully anti-inflammatory. When MSCs are introduced into an environment of chronic inflammation — like a COPD patient’s lungs — they release a cocktail of cytokines and growth factors that essentially tell the immune system to calm down. Not in a blunt, immunosuppressive way like high-dose steroids. More like a reset button.
Second, they appear to encourage existing lung stem cells and progenitor cells to get back to work. There’s evidence suggesting MSCs secrete extracellular vesicles packed with proteins, microRNAs, and other signaling molecules that wake up dormant repair mechanisms in the lung epithelium.
Third — and this is the part that gets the most attention — MSCs have the capacity to differentiate into various cell types and directly participate in tissue regeneration. The extent to which they actually become new lung cells versus supporting the body’s own cells to do that job is still being studied. But clinically, what matters is that patients are reporting measurable improvements in lung function, oxygen saturation, and most importantly, quality of life.
What Treatment Actually Looks Like in Bangkok
Let me walk you through what a real patient experiences when they come to our clinic on Sukhumvit Road.
Take Khun Somchai, a 62-year-old former taxi driver from Ratchaburi province. He smoked for thirty-five years before quitting in 2018, but by then the damage was done. He was diagnosed with moderate-to-severe COPD. By early 2025, he was on supplemental oxygen for about 14 hours a day. Walking from his bedroom to the kitchen left him winded. His daughter, who works in healthcare, started researching alternatives and found us.
Somchai’s treatment protocol was straightforward. Over two sessions spaced roughly four weeks apart, he received intravenous infusions of umbilical cord-derived MSCs — approximately 100 million cells per session. The IV route allows the cells to travel through the bloodstream and, thanks to something called the “first-pass pulmonary effect,” a significant proportion of them naturally lodge in the lungs. For a lung condition, that’s actually an advantage.
He also received a complementary nebulized dose — the cells delivered as a fine mist directly into the airways — during each visit. Combination delivery methods like this are becoming more common as clinics refine their approaches.
Did Somchai wake up the next day and run a marathon? No. That’s not how this works. But here’s what his daughter told us at the three-month follow-up: he was down to six hours of oxygen per day instead of fourteen. He could walk to the local market again, slowly but without stopping every fifty meters. His SpO2 at rest had climbed from 89% to 94%. Small numbers on paper, maybe. Life-changing in practice.
The Numbers: What Does This Cost
People always want to know about pricing, and I believe in being upfront about it. At Cell La Vie, a full COPD or pulmonary fibrosis treatment course — including the initial consultation, lab work, imaging, two MSC infusion sessions, and follow-up monitoring — typically runs between 350,000 and 550,000 Thai Baht. That’s roughly $9,700 to $15,300 USD at current exchange rates.
Is that cheap? Depends on your frame of reference. Compared to a lifetime of medications, oxygen tank refills, hospital admissions, and the lost income from not being able to work — many of our patients tell us it pencils out. Compared to what similar treatment costs in the United States or Europe (easily three to five times that amount), it’s significantly more accessible.
We also offer single-session options starting around 180,000 THB for patients who want to start conservatively and assess their response before committing to a full protocol.
Post-COVID Lung Damage: A Growing Need
One group of patients we’ve been seeing more frequently since 2023 are those with what’s now called post-acute sequelae of SARS-CoV-2 infection — or, in plain English, long COVID with pulmonary involvement.
These cases are different from COPD or IPF in an important way: the patient often had perfectly healthy lungs before COVID. The damage is acute in origin, and in theory, the repair mechanisms should still be functional — they just need the right nudge.
A 41-year-old woman named Nittaya came to us in late 2024. She’d had a severe COVID case in 2022 that put her in the ICU for eleven days. She recovered, technically. The virus cleared. But her CT scans showed ground-glass opacities and early fibrotic changes that weren’t resolving. Her pulmonologist at a government hospital in Bangkok had done everything standard medicine offers — corticosteroids, antifibrotics, pulmonary rehab. She plateaued at about 65% of her pre-COVID lung function.
After one round of MSC therapy with us (IV plus nebulized), her six-month follow-up CT showed significant reduction in the ground-glass opacities. Her pulmonary function tests improved by roughly 18%. She started jogging again — something she genuinely thought she’d never do.
These are the cases that make us optimistic. When the underlying lung architecture isn’t destroyed by years of progressive disease, MSCs seem to have even more room to work their magic.
What the Research Says
We’re not pulling this out of thin air. The clinical evidence base for MSC therapy in respiratory disease has grown substantially over the last five years.
A 2021 systematic review published in Stem Cell Research & Therapy analyzed data from multiple clinical trials involving MSC treatment for COPD and concluded that MSC infusion was associated with significant improvements in lung function parameters and quality-of-life scores, with an excellent safety profile — no serious adverse events attributed to the cells themselves.
For pulmonary fibrosis, a 2023 phase I/II trial published in Chest demonstrated that intravenous administration of bone marrow-derived MSCs was safe and associated with stabilization of lung function decline in patients with idiopathic pulmonary fibrosis over a 12-month follow-up period.
The post-COVID landscape is newer, but multiple studies from 2022 through early 2025 have reported promising results. A randomized controlled trial from China, published in The Lancet Respiratory Medicine, found that MSC infusion in patients with COVID-19-related acute respiratory distress syndrome was associated with reduced mortality and faster recovery of lung function compared to placebo.
It’s worth being honest about what the science doesn’t yet tell us. We don’t have twenty-year longitudinal data. The optimal dosing, timing, and delivery route are still being refined. Not every patient responds dramatically. But the trajectory is clear, and for patients who’ve exhausted conventional options, the risk-benefit calculus often makes sense.
Why Thailand
Medical tourism to Thailand isn’t new — the country has been a destination for everything from cardiac surgery to cosmetic procedures for decades. What’s changed is the regulatory environment for advanced cell therapies.
Thailand’s FDA equivalent has developed frameworks that allow for the clinical use of somatic cell therapy under physician supervision, provided proper manufacturing standards and informed consent protocols are followed. Our MSCs are processed in a GMP-certified cleanroom facility by a partner lab in Bangkok that’s been handling cell products for over a decade.
Combine that regulatory openness with Thai hospitality, internationally trained physicians, and costs that are a fraction of what Western clinics charge, and you start to understand why patients from Australia, the UK, the Middle East, and North America are making the trip.
Plus — and this matters more than most clinics want to admit — you recover better when you’re not stressed. Bangkok has world-class hotels, incredible food, and the kind of warmth (both climatic and human) that makes a two-week treatment visit feel less like a medical procedure and more like a health retreat.
Is This Right for You (or Someone You Love)
We get asked this question every single day. The honest answer involves a conversation, not a blog post. It depends on your specific diagnosis, disease stage, overall health status, and realistic expectations.
But here are some general guidelines we use at our clinic. You might be a good candidate if:
- You have a confirmed diagnosis of COPD, pulmonary fibrosis, or post-COVID lung damage
- You’ve tried standard treatments and are still experiencing significant symptoms or declining function
- You’re not in end-stage disease with widespread, irreversible structural destruction (we review CT scans carefully before accepting any patient)
- You understand that stem cell therapy is about repair and regeneration — not an overnight miracle
- You’re willing to commit to follow-up visits and monitoring so we can track your progress
We don’t overpromise. That’s not how good medicine works. What we do is provide the best possible MSCs, delivered in the most effective way we know, supported by genuine care and honest communication about what you can realistically expect.
The Bottom Line
Lung disease takes things from you. Your breath, yes, but also your independence, your spontaneity, your ability to play with your grandkids without planning it three days in advance. The idea that there might be a therapy that doesn’t just put a band-aid on symptoms but actually helps your body rebuild — that’s powerful.
Stem cell therapy for lung disease is not science fiction anymore. It’s happening. It’s being refined. And for people like Somchai and Nittaya, it’s already made a difference you can measure in more than just FEV1 scores.
If you want to learn more — whether for yourself, a parent, or a patient you’re caring for — our medical team is available for consultations. We review imaging remotely before you even book a flight, so you can get an honest assessment of whether this approach makes sense for your specific situation.
Breathing shouldn’t be a luxury. We’re working to make sure it isn’t.
References
- Ridzuan N, Zakaria N, Widera D, et al. Human umbilical cord mesenchymal stem cell-derived extracellular vesicles ameliorate airway inflammation in a rat model of chronic obstructive pulmonary disease (COPD). Stem Cell Research & Therapy. 2021;12:54. doi:10.1186/s13287-020-02088-6
- Glassberg MK, Minkiewicz J, Toonkel RL, et al. Allogeneic human mesenchymal stem cells in patients with idiopathic pulmonary fibrosis via intravenous delivery (AETHER): a phase I safety clinical trial. Chest. 2017;151(2):367-374. doi:10.1016/j.chest.2016.10.061
- Shi L, Huang H, Lu X, et al. Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial. Signal Transduction and Targeted Therapy. 2021;6:58. doi:10.1038/s41392-021-00488-5
- Lanzoni G, Linetsky E, Correa D, et al. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial. Stem Cells Translational Medicine. 2021;10(5):660-673. doi:10.1002/sctm.20-0472
- Behnke J, Kremer S, Shahzad T, et al. MSC-based therapies in preclinical and clinical settings for COVID-19-related acute respiratory distress syndrome. Frontiers in Immunology. 2020;11:607978. doi:10.3389/fimmu.2020.607978
- Harrell CR, Sadikot R, Pascual J, et al. Mesenchymal stem cell-based therapy of inflammatory lung diseases: current understanding and future perspectives. Stem Cells International. 2019;2019:4236973. doi:10.1155/2019/4236973
- Averyanov A, Koroleva I, Konoplyannikov M, et al. First-in-human high-cumulative-dose stem cell therapy in idiopathic pulmonary fibrosis with rapid lung function decline. Stem Cells Translational Medicine. 2020;9(1):6-16. doi:10.1002/sctm.19-0037